Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific director's share transaction rather than consolidated financial performance.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only change noted is an increase in the notional share interests of Mr. A P Witty.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It details a transaction where Mr. A P Witty acquired 290 Ordinary shares under the dividend re-investment element (personal contribution) and 290 Ordinary shares under the matching element (Company contribution) at a price of £12.73 per share. This followed the re-investment of dividends paid on October 7, 2010.
Investor Verification Points
- Verify the total notional shareholding of Mr. A P Witty following this transaction.
- Confirm the vesting schedule and measurement period for the 2009 Deferred Annual Bonus Plan.
- Check subsequent filings for any further director transactions or changes to the bonus plan structure.